The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics

References

• Baxter AJ, Scott KM, Vos T, et al. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013;43(5):897–910.
   PubMed Web of Science ®Google Scholar
• Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91(9):617–624.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–335.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Yaqubi S, Sayed S, et al. Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs. 2015;20(3):393–406.
   PubMed Web of Science ®Google Scholar
• Stein MB, Sareen J, Solomon CG. Clinical practice. generalized anxiety disorder. N Engl J Med. 2015;373(21):2059–2068.
   PubMed Web of Science ®Google Scholar
• Lohoff FW, Aquino TD, Narasimhan S, et al. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13(1):21–26.
   PubMed Web of Science ®Google Scholar
• Narasimhan S, Aquino TD, Hodge R, et al. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci Lett. 2011;503(3):200–202.
   PubMed Web of Science ®Google Scholar
• Caldirola D, Perna G. Is there a role for pharmacogenetics in the treatment of panic disorder? Pharmacogenomics. 2015;16(8):771–774.
   PubMed Web of Science ®Google Scholar
• Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13(5):464–469.
   PubMed Web of Science ®Google Scholar
• Bishop JR. Pharmacogenetics. Handb Clin Neurol. 2018;147:59–73.
   PubMedGoogle Scholar
• Corponi F, Fabbri C, Serretti A. Pharmacogenetics in psychiatry. Adv Pharmacol. 2018;83:297–331.
   PubMedGoogle Scholar
• Lunenburg C, Gasse C. Pharmacogenetics in psychiatric care, a call for uptake of available applications. Psychiatry Res. 2020;292:113336.
   PubMed Web of Science ®Google Scholar
• ISPG. Genetic testing statement: a statement from the international society of psychiatric genetics: International Society for Psychiatric Genetics (ISPG); 2019 [ updated 2006 Nov 3; cited 2020 Dec 22]. Available from: https://ispg.net/genetic-testing-statement/
   Google Scholar
• Drozda K, Müller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014;34(2):166–184.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Menke A, Müller DJ. Towards pharmacogenetic-based treatment in psychiatry. J Neural Transm (Vienna). 2019;126(1):1–3.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021;54(1):5–17.
   PubMedGoogle Scholar
• Carvalho Henriques B, Yang EH, Lapetina D, et al. How can drug metabolism and transporter genetics inform psychotropic prescribing? Front Genet. 2020;11:491895.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Mills JA, Schroeder H, et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry. 2020;81(5). DOI:https://doi.org/10.4088/JCP.20m13396.
   Google Scholar
• Altar CA, Hornberger J, Shewade A, et al. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry. 2013;25(5):509–533.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 2008;83(5):781–787.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–467.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE, Gammal RS, et al. The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther. 2020;107(1):171–175.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37–44.
   PubMed Web of Science ®Google Scholar
• DPWG. DPWG pharmacogenomic guideline 2021 [cited 2021 Mar 16]. Available from: https://upgx.eu/guidelines/
   Google Scholar
• Quaranta S, Dupouey J, Colle R, et al. Pharmacogenetics of antidepressant drugs: state of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics. Therapie. 2017;72(2):311–318.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Gammal RS, et al. A call for clear and consistent communications regarding the role of pharmacogenetics in antidepressant pharmacotherapy. Clin Pharmacol Ther. 2020;107(1):50–52.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
   PubMed Web of Science ®Google Scholar
• Rossow KM, Aka IT, Maxwell-Horn AC, et al. Pharmacogenetics to predict adverse events associated with antidepressants. Pediatrics. 2020;146(6):e20200957.
   PubMed Web of Science ®Google Scholar
• Aldrich SL, Poweleit EA, Prows CA, et al. Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol. 2019;10:99.
   PubMed Web of Science ®Google Scholar
• Poweleit EA, Aldrich SL, Martin LJ, et al. Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders. J Child Adolesc Psychopharmacol. 2019;29(5):348–361.
   PubMed Web of Science ®Google Scholar
• De Klerk OL, Bosker FJ, Luurtsema G, et al. The role of p-glycoprotein in psychiatric disorders: a reliable guard of the brain? Cent Nerv Syst Agents Med Chem. 2011;11(3):197–209.
   PubMedGoogle Scholar
• Bruckl TM, Uhr M. ABCB1 genotyping in the treatment of depression. Pharmacogenomics. 2016;17(18):2039–2069.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodriguez M, Belmonte C, Roman M, et al. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol. 2018;123(4):474–485.
   PubMed Web of Science ®Google Scholar
• Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008;58(5–6):344–347.
   PubMed Web of Science ®Google Scholar
• Fukui N, Suzuki Y, Sawamura K, et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit. 2007;29(2):185–189.
   PubMed Web of Science ®Google Scholar
• Gassó P, Rodríguez N, Mas S, et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014;14(5):457–462.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodriguez M, Belmonte C, Roman M, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin Pharmacol Toxicol. 2018;122(5):501–511.
   PubMed Web of Science ®Google Scholar
• Laika B, Leucht S, Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem. 2006;52(5):893–895.
   PubMed Web of Science ®Google Scholar
• Ruan CJ, De Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics. 2020;21(6):369–373.
   PubMed Web of Science ®Google Scholar
• Rajkumar AP, Poonkuzhali B, Kuruvilla A, et al. Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatr. 2013;25(1):2–11.
   PubMed Web of Science ®Google Scholar
• Shimoda K, Someya T, Morita S, et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position −2964 in the 5ʹ-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):261–265.
   PubMed Web of Science ®Google Scholar
• Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97(5):296–301.
   PubMed Web of Science ®Google Scholar
• Lerena AL, Dorado P, Berecz R, et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol. 2004;59(12):869–873.
   PubMed Web of Science ®Google Scholar
• He Q, Yuan Z, Liu Y, et al. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenet Genomics. 2017;27(8):279–284.
   PubMed Web of Science ®Google Scholar
• Strug LJ, Suresh R, Fyer AJ, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. 2010;15(2):166–176.
   PubMed Web of Science ®Google Scholar
• Chang HA, Fang WH, Liu YP, et al. Sex-specific pathways among tri-allelic serotonin transporter polymorphism, trait neuroticism and generalized anxiety disorder. J Psychiatry Neurosci. 2020;45(6):379–386.
   PubMed Web of Science ®Google Scholar
• Narasimhan S, Hodge R, Doyle GA, et al. Association analysis between the 5-HTTLPR polymorphism in the SLC6A4 gene and generalized anxiety disorder. Psychiatr Genet. 2011;21(5):267–268.
   PubMed Web of Science ®Google Scholar
• You JS, Hu SY, Chen B, et al. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet. 2005;15(1):7–11.
   PubMed Web of Science ®Google Scholar
• Lonsdorf TB, Ruck C, Bergstrom J, et al. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1479–1483.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Goate AM, Nowotny P, et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J Clin Psychopharmacol. 2010;30(6):672–677.
   PubMed Web of Science ®Google Scholar
• Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473–500.
   PubMed Web of Science ®Google Scholar
• Unschuld PG, Ising M, Erhardt A, et al. Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144b(4):424–429.
   PubMed Web of Science ®Google Scholar
• Lesch KP, Gutknecht L. Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol. 2004;7(4):381–385.
   PubMed Web of Science ®Google Scholar
• Lesch KP, Wiesmann M, Hoh A, et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl). 1992;106(1):111–117.
   PubMed Web of Science ®Google Scholar
• Huang YY, Battistuzzi C, Oquendo MA, et al. Human 5-HT1A receptor C(−1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol. 2004;7(4):441–451.
   PubMed Web of Science ®Google Scholar
• Kim W, Choi YH, Yoon KS, et al. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1413–1418.
   PubMed Web of Science ®Google Scholar
• Zarrindast MR, Khakpai F. The modulatory role of dopamine in anxiety-like behavior. Arch Iran Med. 2015;18(9):591–603.
   PubMed Web of Science ®Google Scholar
• Domschke K, Deckert J. Genetics of anxiety disorders - status quo and quo vadis. Curr Pharm Des. 2012;18(35):5691–5698.
   PubMed Web of Science ®Google Scholar
• Rowe DC, Stever C, Gard JM, et al. The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav Genet. 1998;28(3):215–225.
   PubMed Web of Science ®Google Scholar
• Lawford BR, Young R, Noble EP, et al. The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. Eur Psychiatry. 2006;21(3):180–185.
   PubMed Web of Science ®Google Scholar
• Noble EP, Blum K, Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry. 1991;48(7):648–654.
   PubMed Web of Science ®Google Scholar
• Zhang W, Cao Y, Wang M, et al. The dopamine D2 receptor polymorphism (DRD2 TaqIA) interacts with maternal parenting in predicting early adolescent depressive symptoms: evidence of differential susceptibility and age differences. J Youth Adolesc. 2015;44(7):1428–1440.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SK, Kang WS, et al. Potential involvement of NET polymorphism in serotonin/norepinephrine reuptake inhibitor response in panic disorder. Nord J Psychiatry. 2016;70(4):314–317.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Hohoff C, Domschke K, et al. Norepinephrine transporter (NET) promoter and 5ʹ-UTR polymorphisms: association analysis in panic disorder. Neurosci Lett. 2005;377(1):40–43.
   PubMed Web of Science ®Google Scholar
• Buttenschøn HN, Kristensen AS, Buch HN, et al. The norepinephrine transporter gene is a candidate gene for panic disorder. J Neural Transm (Vienna). 2011;118(6):969–976.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Eikelis N, Bayles RG, et al. A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. Mol Psychiatry. 2017;22(1):134–141.
   PubMed Web of Science ®Google Scholar
• Howe AS, Buttenschon HN, Bani-Fatemi A, et al. Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways. Mol Psychiatry. 2016;21(5):665–679.
   PubMed Web of Science ®Google Scholar
• Tang Z, Zhang S, Guo D, et al. Association between COMT gene Val108/158Met and antidepressive treatment response: a meta-analysis. Gene. 2020;734:144333.
   PubMed Web of Science ®Google Scholar
• Vinkers CH, Kuzminskaite E, Lamers F, et al. An integrated approach to understand biological stress system dysregulation across depressive and anxiety disorders. J Affect Disord. 2021;283:139–146.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mantella RC, Shi P, et al. Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry. 2011;19(5):482–490.
   PubMed Web of Science ®Google Scholar
• Bonfiglio JJ, Inda C, Refojo D, et al. The corticotropin-releasing hormone network and the hypothalamic-pituitary-adrenal axis: molecular and cellular mechanisms involved. Neuroendocrinology. 2011;94(1):12–20.
   PubMed Web of Science ®Google Scholar
• Weber H, Richter J, Straube B, et al. Allelic variation in CRHR1 predisposes to panic disorder: evidence for biased fear processing. Mol Psychiatry. 2016;21(6):813–822.
   PubMed Web of Science ®Google Scholar
• Schartner C, Ziegler C, Schiele MA, et al. CRHR1 promoter hypomethylation: an epigenetic readout of panic disorder? Eur Neuropsychopharmacol. 2017;27(4):360–371.
   PubMed Web of Science ®Google Scholar
• Lutfy K, Shankar G. Emerging evidence for the role of pituitary adenylate cyclase-activating peptide in neuropsychiatric disorders. Prog Mol Biol Transl Sci. 2019;167:143–157.
   PubMed Web of Science ®Google Scholar
• Nam MH, Won W, Han KS, et al. Signaling mechanisms of mu-opioid receptor (MOR) in the hippocampus: disinhibition versus astrocytic glutamate regulation. Cell Mol Life Sci. 2021;78(2):415–426.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Baldwin D, Abelli M, et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017;18(3):162–214.
   PubMed Web of Science ®Google Scholar
• Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089–1093.
   PubMed Web of Science ®Google Scholar
• West AE, Pruunsild P, Timmusk T. Neurotrophins: transcription and translation. Handb Exp Pharmacol. 2014;220:67–100.
   PubMedGoogle Scholar
• Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl). 2006;187(1):68–72.
   PubMed Web of Science ®Google Scholar
• Perna G, Favaron E, Di Bella D, et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology. 2005;30(12):2230–2235.
   PubMed Web of Science ®Google Scholar
• Saeki Y, Watanabe T, Ueda M, et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol. 2009;65(7):685–691.
   PubMed Web of Science ®Google Scholar
• Ishiguro S, Watanabe T, Ueda M, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol. 2011;67(12):1213–1221.
   PubMed Web of Science ®Google Scholar
• Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord. 2010;123(1–3):308–311.
   PubMed Web of Science ®Google Scholar
• Aoki A, Ishiguro S, Watanabe T, et al. Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:1793–1798.
   PubMed Web of Science ®Google Scholar
• Woo JM, Yoon KS, Choi YH, et al. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res. 2004;38(4):365–370.
   PubMed Web of Science ®Google Scholar
• Yang J, Li S, Lv H, et al. CREB1 and BDNF gene polymorphisms are associated with early treatment response to escitalopram in panic disorder. J Affect Disord. 2021;278:536–541.
   PubMed Web of Science ®Google Scholar
• Narasimhan S, Aquino TD, Multani PK, et al. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2012;198(1):112–115.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Narasimhan S, Rickels K, et al. Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2013;210(3):1299–1300.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Rickels K, Lohoff FW. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Hum Psychopharmacol. 2013;28(3):258–262.
   PubMed Web of Science ®Google Scholar
• Saung WT, Narasimhan S, Lohoff FW. Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder. Hum Psychopharmacol. 2014;29(4):316–321.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Fijal B, Dharia S, et al. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J. 2013;13(3):280–285.
   PubMed Web of Science ®Google Scholar
• Ball S, Marangell LB, Lipsius S, et al. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:217–221.
   PubMed Web of Science ®Google Scholar
• Kronenberg S, Apter A, Brent D, et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol. 2007;17(6):741–750.
   PubMed Web of Science ®Google Scholar
• Jung J, Tawa EA, Muench C, et al. Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2017;254:8–11.
   PubMed Web of Science ®Google Scholar
• Li QS, Wajs E, Ochs-Ross R, et al. Genome-wide association study and polygenic risk score analysis of esketamine treatment response. Sci Rep. 2020;10(1):12649.
   PubMed Web of Science ®Google Scholar
• Santoro ML, Ota V, de Jong S, et al. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. Transl Psychiatry. 2018;8(1):174.
   PubMedGoogle Scholar
• Tomasi J, Lisoway AJ, Zai CC, et al. Towards precision medicine in generalized anxiety disorder: review of genetics and pharmaco(epi)genetics. J Psychiatr Res. 2019;119:33–47.
   PubMed Web of Science ®Google Scholar
• García-González J, Tansey KE, Hauser J, et al. Pharmacogenetics of antidepressant response: a polygenic approach. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:128–134.
   PubMed Web of Science ®Google Scholar
• Roberts S, Lester KJ, Hudson JL, et al. Serotonin transporter [corrected] methylation and response to cognitive behaviour therapy in children with anxiety disorders. Transl Psychiatry. 2014;4(9):e444.
   PubMedGoogle Scholar
• Roberts S, Keers R, Lester KJ, et al. HPA axis related genes and response to psychological therapies: genetics and epigenetics. Depress Anxiety. 2015;32(12):861–870.
   PubMed Web of Science ®Google Scholar
• Roberts S, Keers R, Breen G, et al. DNA methylation of FKBP5 and response to exposure-based psychological therapy. Am J Med Genet B Neuropsychiatr Genet. 2019;180(2):150–158.
   PubMed Web of Science ®Google Scholar
• Ziegler C, Richter J, Mahr M, et al. MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy. Transl Psychiatry. 2016;6(4):e773.
   PubMedGoogle Scholar
• Schiele MA, Ziegler C, Kollert L, et al. Plasticity of functional MAOA gene methylation in acrophobia. Int J Neuropsychopharmacol. 2018;21(9):822–827.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li M, Wang X, et al. Drug response-related DNA methylation changes in Schizophrenia, bipolar disorder, and major depressive disorder. Front Neurosci. 2021;15:674273.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78(6):720–729.
   PubMed Web of Science ®Google Scholar
• Bradley P, Shiekh M, Mehra V, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:100–107.
   PubMed Web of Science ®Google Scholar
• Meier SM, Deckert J. Genetics of anxiety disorders. Curr Psychiatry Rep. 2019;21(3):16.
   PubMed Web of Science ®Google Scholar
• Otowa T, Hek K, Lee M, et al. Meta-analysis of genome-wide association studies of anxiety disorders. Mol Psychiatry. 2016;21(10):1391–1399.
   PubMed Web of Science ®Google Scholar
• Purves KL, Coleman JRI, Meier SM, et al. A major role for common genetic variation in anxiety disorders. Mol Psychiatry. 2020;25(12):3292–3303.
   PubMed Web of Science ®Google Scholar
• Meier SM, Trontti K, Purves KL, et al. Genetic variants associated with anxiety and stress-related disorders: a genome-wide association study and mouse-model study. JAMA Psychiatry. 2019;76(9):924–932.
   PubMed Web of Science ®Google Scholar
• Otowa T, Kawamura Y, Sugaya N, et al. Association study of PDE4B with panic disorder in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):545–549.
   PubMed Web of Science ®Google Scholar
• Deckert J, Weber H, Villmann C, et al. GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder. Mol Psychiatry. 2017;22(10):1431–1439.
   PubMed Web of Science ®Google Scholar
• Lueken U, Kuhn M, Yang Y, et al. Modulation of defensive reactivity by GLRB allelic variation: converging evidence from an intermediate phenotype approach. Transl Psychiatry. 2017;7(9):e1227.
   PubMedGoogle Scholar
• Reinecke A, Nickless A, Browning M, et al. Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: a randomized placebo-controlled trial. Behav Res Ther. 2020;129:103607.
   PubMed Web of Science ®Google Scholar
• Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11.
   PubMedGoogle Scholar
• Spierling SR, Zorrilla EP. Don’t stress about CRF: assessing the translational failures of CRF(1)antagonists. Psychopharmacology (Berl). 2017;234(9–10):1467–1481.
   PubMed Web of Science ®Google Scholar
• Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther. 2019;204:107402.
   PubMed Web of Science ®Google Scholar